{"id":"recombinant-human-albumin-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Hypervolemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Recombinant human albumin is a recombinantly produced version of the most abundant plasma protein. It functions to restore and maintain intravascular oncotic pressure, expand plasma volume in hypovolemic states, and serve as a carrier for various endogenous and exogenous substances. It is used as a therapeutic agent in conditions requiring volume replacement and protein supplementation.","oneSentence":"Recombinant human albumin acts as a plasma volume expander and carrier protein to maintain oncotic pressure and transport endogenous substances.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:33.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypovolemia and shock management"},{"name":"Plasma protein replacement in critical illness"},{"name":"Albumin deficiency states"}]},"trialDetails":[{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT06489015","phase":"EARLY_PHASE1","title":"Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials","status":"ACTIVE_NOT_RECRUITING","sponsor":"Protgen Ltd","startDate":"2024-06-28","conditions":"Alzheimer's Disease (AD)","enrollment":30},{"nctId":"NCT05858853","phase":"PHASE2, PHASE3","title":"Phase II/III of Recombinant Human Serum Albumin","status":"COMPLETED","sponsor":"Protgen Ltd","startDate":"2023-05-24","conditions":"Cirrhotic Ascites","enrollment":92},{"nctId":"NCT03949855","phase":"PHASE2","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-06","conditions":"Membranous Nephropathy, Nephrotic Syndrome","enrollment":58},{"nctId":"NCT07150767","phase":"PHASE1","title":"A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","startDate":"2025-03-26","conditions":"Locally Advanced Breast Cancer (LABC)","enrollment":""},{"nctId":"NCT06911554","phase":"PHASE3","title":"A Study of Recombinant Human Albumin Injection to Treat Hypoalbuminemia in Cirrhotic Patients With Ascites","status":"COMPLETED","sponsor":"Tonghua Anrate Biopharmaceutical Co., Ltd.","startDate":"2023-06-16","conditions":"Hepatic Ascites","enrollment":416},{"nctId":"NCT03563157","phase":"PHASE1, PHASE2","title":"QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-09-28","conditions":"Colorectal Cancer Metastatic, mCRC","enrollment":2},{"nctId":"NCT06411743","phase":"PHASE2","title":"Phase II/III of Recombinant Human Albumin Injection","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2021-09-07","conditions":"Hepatic Ascites","enrollment":90},{"nctId":"NCT00837265","phase":"PHASE2, PHASE3","title":"Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2008-08-21","conditions":"Chemotherapy-induced Neutropenia","enrollment":334},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT06136988","phase":"PHASE1, PHASE2","title":"A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-12","conditions":"Locally Advanced Unresectable Esophageal Squamous Carcinoma","enrollment":129},{"nctId":"NCT02549170","phase":"PHASE3","title":"A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-12-15","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":138},{"nctId":"NCT01126190","phase":"PHASE3","title":"Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-06-30","conditions":"Chemotherapy-induced Neutropenia","enrollment":381},{"nctId":"NCT04554056","phase":"PHASE2, PHASE3","title":"Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF","status":"COMPLETED","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2020-09-21","conditions":"Breast Cancer Female","enrollment":586},{"nctId":"NCT00432523","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-01-20","conditions":"Measles, Mumps, Varicella","enrollment":752},{"nctId":"NCT05068141","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-10-01","conditions":"Triple Negative Breast Cancer","enrollment":79},{"nctId":"NCT02910466","phase":"PHASE4","title":"A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism","status":"COMPLETED","sponsor":"Shire","startDate":"2016-10-27","conditions":"Chronic Hypoparathyroidism, Hypoparathyroidism","enrollment":39},{"nctId":"NCT03563170","phase":"PHASE1, PHASE2","title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-25","conditions":"Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent","enrollment":""},{"nctId":"NCT04701697","phase":"PHASE1","title":"Phase Ib of Recombinant Human Albumin Injection","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2020-03-15","conditions":"Ascites","enrollment":36},{"nctId":"NCT01181128","phase":"PHASE3","title":"Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2010-11","conditions":"Severe Hemophilia A","enrollment":165},{"nctId":"NCT04641364","phase":"PHASE1","title":"Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2019-06-24","conditions":"Ascites","enrollment":80},{"nctId":"NCT03786289","phase":"PHASE1","title":"Study on Single Administration and Dose Increment of Recombinant Human Serum Albumin/Erythrocyte Fusion Protein for Injection","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2018-12-03","conditions":"Healthy Subjects","enrollment":34},{"nctId":"NCT04239001","phase":"NA","title":"Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-02","conditions":"Advanced Pancreatic Cancer","enrollment":20},{"nctId":"NCT03251768","phase":"PHASE2","title":"Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2017-10-19","conditions":"Chemotherapy-induced Neutropenia","enrollment":80},{"nctId":"NCT00566527","phase":"PHASE3","title":"Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-29","conditions":"Measles, Mumps, Rubella","enrollment":1620},{"nctId":"NCT00560755","phase":"PHASE3","title":"Safety Study of ProQuad® rHA in Infants (V221-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10-24","conditions":"Measles, Mumps, Rubella","enrollment":3388},{"nctId":"NCT02643901","phase":"PHASE1","title":"Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu T-Mab Biopharma Co.,Ltd","startDate":"2015-09","conditions":"Chemotherapy-induced Neutropenia","enrollment":26},{"nctId":"NCT02725606","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu T-Mab Biopharma Co.,Ltd","startDate":"2016-03","conditions":"Chemotherapy-induced Neutropenia","enrollment":30},{"nctId":"NCT03246009","phase":"PHASE1","title":"Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2016-01-21","conditions":"Chemotherapy-induced Neutropenia, Cancer, Breast","enrollment":24},{"nctId":"NCT02465801","phase":"PHASE2","title":"Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2014-12-16","conditions":"Chemotherapy-induced Neutropenia","enrollment":216},{"nctId":"NCT02479581","phase":"PHASE2","title":"The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2015-07","conditions":"Valvular Heart Disease","enrollment":226},{"nctId":"NCT02156388","phase":"PHASE1","title":"Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors","status":"COMPLETED","sponsor":"Jiangsu T-Mab Biopharma Co.,Ltd","startDate":"2013-08","conditions":"Chemotherapy-induced Neutropenia, Metastatic Tumors","enrollment":31},{"nctId":"NCT01887366","phase":"PHASE2","title":"Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-06","conditions":"Cocaine Addiction","enrollment":208}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intravenous infusion of human albumin injection","Intravenous infusion of recombinant human albumin injection"],"phase":"phase_3","status":"active","brandName":"Recombinant Human Albumin Injection","genericName":"Recombinant Human Albumin Injection","companyName":"The First Hospital of Jilin University","companyId":"the-first-hospital-of-jilin-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant human albumin acts as a plasma volume expander and carrier protein to maintain oncotic pressure and transport endogenous substances. Used for Hypovolemia and shock management, Plasma protein replacement in critical illness, Albumin deficiency states.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}